SEL-PLEX Selenium Modulates Alzheimer Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current selenium treatments for neurodegenerative diseases lack specificity in targeting genes associated with disease and aging, and there is a need to identify effective forms of selenium for customized treatments that minimize toxicity while maximizing beneficial effects on nervous, endocrine, and metabolic systems.
Innovation Solution
The use of specific forms of selenium, such as SEL-PLEX, which are administered to alter gene expression in the cerebral cortex, specifically reducing the expression of genes like C1q, Cathepsin, presenilin, and nicastrin to inhibit the processing of amyloid precursor protein and reduce Alzheimer's disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inorganic selenium compounds (e.g., sodium selenate, selenite) are used for treatment, then some health benefits are observed at low doses, but toxicity increases significantly at elevated dosage levels
Solution Approach 1:
The patent changes the chemical form of selenium from inorganic compounds (selenate, selenite) to organic selenium compounds (selenomethionine, selenocysteine, seleno-taurine). This parameter change in chemical form fundamentally alters the safety profile, allowing therapeutic doses to be administered without the severe toxicity associated with inorganic selenium compounds at elevated doses.
Solution Approach 2:
The patent employs selenium compounds with short biological half-lives and rapid excretion characteristics. The organic selenium compounds used (particularly selenomethionine) are metabolized and excreted quickly, preventing accumulation and chronic toxicity. This temporal characteristic allows repeated dosing without building up harmful levels in the body.
2Reliability
If selenium is provided at doses 5- to 10-fold above nutritional requirement for cancer prevention, then cancer incidence is reduced in animal models, but the safety margin is narrowed
Solution Approach 1:
The patent changes the biochemical utilization parameters of selenium by using organic forms that are incorporated into proteins and enzymes. This allows effective selenium status to be maintained at lower doses compared to inorganic forms, thereby preserving the safety margin while still achieving cancer prevention benefits observed in animal models.
Solution Approach 2:
The organic selenium compounds automatically regulate their own utilization through incorporation into cellular proteins and enzymes. The body self-regulates selenium metabolism by incorporating it into functional molecules where it is needed, preventing both deficiency and excess accumulation. This self-regulating mechanism maintains safety margins even at therapeutic doses.
3Reliability
If specific forms of selenium are used to target genes associated with Alzheimer's disease, then beneficial effects on nervous system function are achieved, but the complexity of selecting and administering the correct selenium form increases
Solution Approach 1:
The patent identifies organic selenium compounds that serve multiple functions simultaneously: they act as antioxidants, modulate gene expression related to Alzheimer's disease (reducing C1q, cathepsin, presenilin, nicastrin), and support general nervous system health. This multi-functionality allows a single selenium form to address multiple needs without requiring complex combination therapies.
Solution Approach 2:
The patent uses organic selenium compounds as intermediary substances that mediate between dietary selenium intake and specific therapeutic effects. These compounds serve as bioavailable carriers that deliver selenium to target tissues (particularly the brain) and facilitate specific gene expression changes, simplifying the pathway from supplementation to therapeutic outcome.
Data Source
AI summary
The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment for neurodegenerative disease). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX) possess the ability to alter expression of genes associated with disease and/or aging while other forms of selenium (e.g., selenomethionine) do not.